This page isn’t medical advice. It has no provider buttons. It sums up what the drug labels tell prescribers and patients, so you know which questions to ask.
Don’t take two GLP-1 drugs at once. The Foundayo label says so directly. The same goes for tirzepatide, which also acts on the GLP-1 receptor.
The heading reads “Risk of thyroid C-cell tumors.” In studies in rats and mice, these drugs caused thyroid C-cell tumors. Nobody knows yet whether they do the same in people. That’s why a personal or family history of MTC or MEN 2 rules them out.
The labels ask you to tell your prescriber about a lump or swelling in your neck, trouble swallowing, a hoarse voice that doesn’t go away, or shortness of breath.
| Warning | Wegovy and Wegovy pill | Zepbound | Foundayo |
|---|---|---|---|
| Thyroid C-cell tumors (boxed) | Yes | Yes | Yes |
| Acute pancreatitis | Yes | Yes | Yes |
| Acute gallbladder disease | Yes | Yes | Yes |
| Severe stomach and bowel reactions | Yes | Yes | Yes |
| Kidney injury from dehydration | Yes | Yes | Yes |
| Low blood sugar | Yes | Yes | Yes |
| Serious allergic reactions | Yes | Yes | Yes |
| Diabetic eye disease getting worse | Yes | Yes | Yes |
| Inhaling food under anesthesia | Yes | Yes | Yes |
| Faster heart rate | Yes | Not listed | Not listed |
| Label revised | June 2026 | August 2026 | July 2026 |
Sources: the Wegovy label, the Zepbound label and the Foundayo label on DailyMed. Ozempic and Mounjaro are approved for type 2 diabetes and carry the same boxed warning. Each medication page has its own details.
As of May 31, 2026, the FDA had received 990 adverse event reports linked to compounded semaglutide and more than 730 linked to compounded tirzepatide. Some patients ended up in the hospital after dosing mistakes, such as drawing the wrong amount from a vial or following a dose schedule that rose faster than the approved one. The FDA also says it doesn’t know whether the salt forms some compounders use, semaglutide sodium and semaglutide acetate, work like the approved drug.
If you go the compounded route, these checks follow from the FDA’s warnings:
Source: FDA’s concerns with unapproved GLP-1 drugs used for weight loss, updated October 1, 2026.
For everyday side effects, like nausea, constipation and fatigue, and how long they last, see our GLP-1 side effects guide.
It depends on the type. The labels rule GLP-1s out if you or a family member has had medullary thyroid carcinoma (MTC) or if you have MEN 2. Other thyroid cancers aren’t on that list, but tell your prescriber about any thyroid history.
At least 2 months before you plan to conceive, according to the Wegovy label. Semaglutide stays in the body for weeks, so it needs time to clear.
Tirzepatide (Zepbound, Mounjaro) and Foundayo can make birth control pills less reliable. Their labels say to switch to a non-oral method, or add a barrier method, for about a month after you start and after each dose increase.
Ask your surgeon and anesthesia team. The labels warn that food can stay in the stomach and be inhaled under general anesthesia or deep sedation, so they need to know you take a GLP-1.
The FDA can’t say, because it doesn’t review compounded drugs for safety, effectiveness or quality. It has received hundreds of adverse event reports about them, many tied to dosing mistakes.
Looking for More Answers?
View the full GLP-1 FAQ or email us at [email protected]
Medical Disclaimer: This page is for information only and isn’t medical advice. GLP-1 medications require a prescription from a licensed provider, who decides whether treatment is right for you. Compounded semaglutide and tirzepatide are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality.